Clinical effectiveness and safety of vildagliptin in >19000 patients with type 2 diabetes: The GUARD study

Diabetes, Obesity and Metabolism

Volumn 17, Issue 6, 2015, Pages 603-607

  Rosales, R ^a   Abou Jaoude, E ^b   Al Arouj, M ^c   Fawwad, A ^d   Orabi, A ^e   Shah, P ^f   Ditommaso, S ^g   Vaz, J ^h   Latif, Z A ⁱ  

^a ST LUKE S MEDICAL CENTER   (Philippines)

^b Middle East Institute of Health   (Lebanon)

^c DASMAN DIABETES INSTITUTE   (Kuwait)

^d BAQAI MEDICAL UNIVERSITY   (Pakistan)

^e ZAGAZIG UNIVERSITY   (Egypt)

^f Silver Brook A   (India)

^g NOVARTIS PHARMA AG   (Switzerland)

^h Novartis Healthcare Pvt Ltd   (India)

ⁱ BIRDEM Hospital   (Bangladesh)

Author keywords

Dipeptidyl peptidase 4 (DPP 4); Incretins; Type 2 diabetes; Vildagliptin

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; METFORMIN PLUS VILDAGLIPTIN; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN; METFORMIN; NITRILE; PYRROLIDINE DERIVATIVE;

ADULT; CLINICAL EFFECTIVENESS; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; WEIGHT CONTROL; AGED; ANALOGS AND DERIVATIVES; BLOOD; BODY MASS; BODY WEIGHT; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADAMANTANE; ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NITRILES; PROSPECTIVE STUDIES; PYRROLIDINES; TREATMENT OUTCOME;

EID: 84928435649     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12436     Document Type: Letter

References (10)

1. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas. Accessed July 2014.
2. García-Pérez LE, Alvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 2013; 4: 175-194.
3. Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab 2012; 14: 228-233.
4. Mendes AB, Fittipaldi JA, Neves RC, Chacra AR, Moreira ED Jr. Prevalence and correlates of inadequate glycaemic control: results from a nationwide survey in 6, 671 adults with diabetes in Brazil. Acta Diabetol 2010; 47: 137-145.
5. Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2014; 74: 587-610.
6. Matthews DR, Dejager S, Ahren B et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010; 12: 780-789.
7. Mathieu C, Barnett AH, Brath H et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract 2013; 67: 947-956.
8. Göke R, Gruenberger JB, Bader G, Dworak M. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany. Curr Med Res Opin 2014; 30: 785-789.
9. Blüher M, Kurz I, Dannenmaier S, Dworak M. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World J Diabetes 2012; 3: 161-169.
10. Schweizer A, Dejager S, Foley JE, Kothny W. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag 2011; 7: 49-57.